Mycoses · 2025
Utility of MALDI-ToF MS for Recognition and Antifungal Susceptibility of Nannizzia, an Underestimated Group of Dermatophytes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Chao, Kong Xue, Jansen Jasmijn, Vossgroene Katharina, Vu Thi-Lam-An, Oberheitmann Boris, Tehupeiory-Kooreman Marlou, Zhou Shaoqin, Zhou Xin, Tsui Clement Kin-Ming, Liu Weida, Kang Yingqian, Ahmed Sarah A, de Hoog Sybren
Аннотация
BACKGROUND: Geophilic Nannizzia dermatophytes are increasingly implicated in stubborn skin, hair, and nail infections, yet MALDI-TOF MS evaluations and antifungal-susceptibility data have focused almost exclusively on N. gypsea. Biochemical profiles and MICs cut-offs are limited.
OBJECTIVES: To benchmark two commercial MALDI-TOF MS libraries and to determine in vitro activity of eight antifungals against a genus-wide panel of Nannizzia species.
METHODS: One-hundred-and-three ITS-confirmed isolates representing 12 species were grown on potato-dextrose agar (PDA) for 7-14 days. Spectra were acquired with (i) the MSI-2 Dermatophyte Library after 4-14 days' PDA incubation (100 cultures) and (ii) the Bruker MALDI Biotyper Filamentous-Fungi Library 6.0/2023 after ≤ 3 days' growth in Sabouraud-dextrose broth (SDB) (73 cultures). BCCM/IHEM strains could not be evaluated on the Biotyper because of licence restrictions, leaving 73 non-duplicate isolates for direct MSI-2 vs MBT comparison. EUCAST E.Def 11.0 micro-broth dilution determined MICs for eight agents.
RESULTS: MSI-2 achieved its highest accuracy with PDA day-7 cultures (45/73, 62%), whereas the liquid Biotyper protocol yielded 49/73 correct identifications (67%) within four days. Accepting low-confidence scores (≥ 1.7) from either library increased overall accuracy to 73%. MSI-2 remained superior for N. gypsea (73%) and uniquely detected N. nana (50%), which is absent from the current Biotyper release. Conversely, the Biotyper outperformed MSI-2 for N. incurvata, N. fulva, and N. praecox. Six very rare species (N. lorica, N. aenigmatica, N. corniculata, N. duboisii, N. perplicata, N. polymorpha) were not recognised by either database. Terbinafine displayed the lowest geometric mean MIC (0.009 mg/L); fluconazole and griseofulvin showed the highest values, and one US N. fulva isolate exhibited elevated itraconazole/voriconazole MICs (1 mg/L).
CONCLUSIONS: Diagnostic coverage of Nannizzia remains incomplete. Expanding commercial MALDI-ToF MS libraries with spectra from rare species and performing routine susceptibility testing are essential to optimise patient management.
OBJECTIVES: To benchmark two commercial MALDI-TOF MS libraries and to determine in vitro activity of eight antifungals against a genus-wide panel of Nannizzia species.
METHODS: One-hundred-and-three ITS-confirmed isolates representing 12 species were grown on potato-dextrose agar (PDA) for 7-14 days. Spectra were acquired with (i) the MSI-2 Dermatophyte Library after 4-14 days' PDA incubation (100 cultures) and (ii) the Bruker MALDI Biotyper Filamentous-Fungi Library 6.0/2023 after ≤ 3 days' growth in Sabouraud-dextrose broth (SDB) (73 cultures). BCCM/IHEM strains could not be evaluated on the Biotyper because of licence restrictions, leaving 73 non-duplicate isolates for direct MSI-2 vs MBT comparison. EUCAST E.Def 11.0 micro-broth dilution determined MICs for eight agents.
RESULTS: MSI-2 achieved its highest accuracy with PDA day-7 cultures (45/73, 62%), whereas the liquid Biotyper protocol yielded 49/73 correct identifications (67%) within four days. Accepting low-confidence scores (≥ 1.7) from either library increased overall accuracy to 73%. MSI-2 remained superior for N. gypsea (73%) and uniquely detected N. nana (50%), which is absent from the current Biotyper release. Conversely, the Biotyper outperformed MSI-2 for N. incurvata, N. fulva, and N. praecox. Six very rare species (N. lorica, N. aenigmatica, N. corniculata, N. duboisii, N. perplicata, N. polymorpha) were not recognised by either database. Terbinafine displayed the lowest geometric mean MIC (0.009 mg/L); fluconazole and griseofulvin showed the highest values, and one US N. fulva isolate exhibited elevated itraconazole/voriconazole MICs (1 mg/L).
CONCLUSIONS: Diagnostic coverage of Nannizzia remains incomplete. Expanding commercial MALDI-ToF MS libraries with spectra from rare species and performing routine susceptibility testing are essential to optimise patient management.